FOLD

14.27

0.21% 0.03

Dopo l'orario di chiusura: 14.25 -0.02 -0.14%

Amicus Therapeutics Inc (FOLD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché FOLD Giù? Forum Previsione

Precedente Chiudi:

$14.24

Aprire:

$14.245

Volume 24 ore:

8.08M

Relative Volume:

0.93

Capitalizzazione di mercato:

$4.41B

Reddito:

$571.16M

Utile/perdita netta:

$-38.10M

Rapporto P/E:

-116.49

EPS:

-0.1225

Flusso di cassa netto:

$-48.91M

1 W Prestazione:

+0.14%

1M Prestazione:

+46.66%

6M Prestazione:

+139.83%

1 anno Prestazione:

+53.28%

Intervallo 1D:

$14.23

$14.27

Intervallo di 1 settimana:

$14.23

$14.28

Portata 52W:

$5.51

$14.36

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Nome

Amicus Therapeutics Inc

Settore

Healthcare (1131)

Industria

Biotechnology (631)

Telefono

(609) 662-2000

Indirizzo

47 HULFISH STREET, PRINCETON, NJ

Dipendente

499

Cinguettio

@amicusrx1

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

FOLD's Discussions on Twitter

Confronta FOLD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FOLD Amicus Therapeutics Inc	14.27	4.40B	571.16M	-38.10M	-48.91M	-0.1225
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-29	Downgrade	Leerink Partners	Outperform → Market Perform
2025-12-22	Downgrade	TD Cowen	Buy → Hold
2025-12-17	Iniziato	Citigroup	Buy
2025-09-18	Aggiornamento	Needham	Hold → Buy
2025-07-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-13	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-09-06	Iniziato	Jefferies	Buy
2024-05-30	Iniziato	Wells Fargo	Overweight
2024-05-14	Aggiornamento	Guggenheim	Neutral → Buy
2023-12-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-04-13	Ripresa	Goldman	Neutral
2022-01-14	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-11-15	Aggiornamento	Stifel	Hold → Buy
2021-09-30	Aggiornamento	JP Morgan	Neutral → Overweight
2021-07-19	Ripresa	BTIG Research	Buy
2021-05-27	Iniziato	Needham	Hold
2021-05-21	Iniziato	UBS	Buy
2021-04-14	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2021-03-02	Iniziato	Stifel	Hold
2021-02-12	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-28	Ripresa	Cantor Fitzgerald	Overweight
2020-12-10	Downgrade	Citigroup	Buy → Neutral
2020-11-11	Iniziato	Berenberg	Hold
2020-06-17	Iniziato	BTIG Research	Buy
2020-02-04	Ripresa	Cantor Fitzgerald	Overweight
2019-11-12	Reiterato	H.C. Wainwright	Buy
2019-06-17	Iniziato	H.C. Wainwright	Buy
2019-06-05	Reiterato	Cantor Fitzgerald	Overweight
2019-04-05	Iniziato	Janney	Buy
2019-01-30	Iniziato	Cantor Fitzgerald	Overweight
2018-10-29	Iniziato	Citigroup	Neutral
2018-08-17	Downgrade	Chardan Capital Markets	Buy → Neutral
2017-10-06	Ripresa	Goldman	Neutral
2017-09-13	Reiterato	Chardan Capital Markets	Buy
2017-08-10	Reiterato	Chardan Capital Markets	Buy
2017-01-24	Aggiornamento	Robert W. Baird	Neutral → Outperform
2016-05-18	Iniziato	BofA/Merrill	Buy
2016-04-14	Iniziato	Robert W. Baird	Neutral
2016-04-12	Reiterato	Chardan Capital Markets	Buy
2015-09-16	Downgrade	Chardan Capital Markets	Buy → Neutral
2015-06-16	Reiterato	Chardan Capital Markets	Buy

Mostra tutto

Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie

Jan 02, 2026

BioMarin's $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent

Jan 02, 2026

Jan 01, 2026

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent

Jan 01, 2026

HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN

Jan 01, 2026

H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey

Jan 01, 2026

H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz

Jan 01, 2026

Dec 31, 2025

Amicus Therapeutics Earnings Notes - Trefis

Dec 31, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Dec 31, 2025

Dec 30, 2025

BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha

Dec 30, 2025

Can Religare Enterprises Limited Stock Deliver Alpha in a Choppy MarketFundamental Stock Analysis & Free Navigate Market With Precision - earlytimes.in

Dec 30, 2025

Amicus Therapeutics (NASDAQ:FOLD) Nasdaq 100 Index Precision Biotech - Kalkine Media

Dec 30, 2025

Dec 29, 2025

BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma

Dec 29, 2025

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga

Dec 29, 2025

FOLD: Analyst Downgrade and Price Target Adjustments | FOLD Stoc - GuruFocus

Dec 29, 2025

Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by Leerink Partners - MarketBeat

Dec 29, 2025

Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17 - marketscreener.com

Dec 29, 2025

Leerink Partners downgrades Amicus Therapeutics stock on BioMarin acquisition By Investing.com - Investing.com UK

Dec 29, 2025

Dec 28, 2025

Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN

Dec 28, 2025

Dec 27, 2025